Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: January 18, 2020

DrugPatentWatch Database Preview

Drug Price Trends for EZETIMIBE

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Drug Price Trends for EZETIMIBE

Average Pharmacy Cost for EZETIMIBE

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
EZETIMIBE 10 MG TABLET 16729-0433-16 0.21121 EACH 2020-01-01
EZETIMIBE 10 MG TABLET 16729-0433-15 0.21121 EACH 2020-01-01
EZETIMIBE 10 MG TABLET 16729-0433-10 0.21121 EACH 2020-01-01
EZETIMIBE-SIMVASTATIN 10-80 MG 69238-1158-09 2.28407 EACH 2019-12-18
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for EZETIMIBE

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Unit Dates Price Type
EZETIMIBE 10MG TAB,UD Major Pharmaceuticals 00904-6664-04 3X10 215.92 2018-12-01 - 2023-11-30 FSS
ZETIA 10MG TAB, UD Merck Sharp & Dohme Corporation 66582-0414-28 100UD 1130.58 11.30580 EACH 2019-01-01 - 2023-08-31 FSS
VYTORIN 10MG/10MG/TAB Merck Sharp & Dohme Corporation 66582-0311-82 1000 11197.69 11.19769 EACH 2018-09-01 - 2023-08-31 FSS
VYTORIN 10MG/40MG TAB UU Merck Sharp & Dohme Corporation 66582-0313-54 90 1007.79 11.19767 EACH 2020-01-01 - 2023-08-31 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Unit >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.